生物制药公司Arcus Biosciences Inc.（股票代码：RCUS）今日盘前股价大跌6.39%，引发市场关注。
据悉，此次股价下跌主要源于公司在周四晚间宣布的一项2.5亿美元的后续股票发行。Arcus Biosciences以每股18.25美元的价格发行了1370万股新股，较之前的股价有9.6%的折扣。这一消息导致投资者对公司股票的估值产生了担忧，从而引发了股价下跌。
公司表示，此次募集的资金将主要用于持续的研发工作，包括扩大其肾癌疗法casdatifan的临床开发计划，以及开发免疫学和炎症产品组合。尽管公司有明确的资金使用计划，但大规模的股票发行inevitably会对现有股东的权益造成稀释。
值得注意的是，尽管此次股价下跌，Arcus Biosciences的股票今年以来仍有不俗表现，截至周四收盘累计上涨约36%。同时，分析师对公司前景持积极态度，13位分析师中有11位给予"强力买入"或"买入"评级，目标价中值为29美元，高于一个月前的25美元。然而，这次大规模融资可能会在短期内对股价造成压力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.